Dexter Yan

Price In China Still High China's CARsgen obtains domestic approval for its anti-Claudin 18.2 CAR-T therapy satri-cel for heavily pretreated gastric or gastroesophageal junction cancer with limited treatment options and poor prognosis, but its price means limited commercial opportunities. Satri-cel is the world’s first approved CAR-T cell therapy for the treatment of gastric or gastroesophageal junction (G/GEJ) cancer.

As multinationals switched to partly supplying global markets from manufacturing facilities in China, the country’s exports of GLP-1 and insulin analog preparations surged in 2025 and well into 2026. China has reported explosive growths in the exports of GLP-1 peptide and insulin analog preparations. (Shutterstock) Chinese-developed GLP-1 receptor agonists and insulin analogs probably have a long way to go before they clinch decent shares of the global obesity and diabetes markets.

Head-To-Head Trial Ongoing Lupeng’s rocbrutinib was conditionally approved for the third-line treatment of mantle cell lymphoma in China on June 4. The molecule is also currently being evaluated in a global head-to-head Phase III trial versus Jaypirca for second-line chronic lymphocytic leukemia/small lymphocytic lymphoma. Rocbrutinib has won regulatory greenlight for a rare hematologic malignancy in China.